Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates

Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.2 per share a year ago.